EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective

Jun 1, 2024, 00:00
10.1016/j.jval.2024.03.664
https://www.valueinhealthjournal.com/article/S1098-3015(24)00779-4/fulltext
Title : EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(24)00779-4&doi=10.1016/j.jval.2024.03.664
First page :
Section Title :
Open access? : No
Section Order : 10138
Categories :
Tags :
Regions :
ViH Article Tags :